Lyell Immunitarma对最近的ASH数据和免疫疗法扩展发表看法

2025-12-23 03:56

Lyell Immunopharma (LYEL) is up ~17% on Monday as investors appear to digest positive data from one of its CAR-T blood cancer therapies presented earlier in December at the American Society of Hematology Annual Meeting.
In addition, the company is seen as potentially benefitting from the label expansion in November of AbbVie (ABBV) and Genmab's (GMAB) bi-specific antibody Epkinly (epcoritamab) as a second-line follicular lymphoma treatment.
New data on CAR-T therapy rondecabtagene autoleucel (ronde-cel) in patients with large B-cell lymphoma presented at ASH found an 83% overall response and 61% complete response rates in a second-line setting. Also, 70% of patients with a complete response maintained it for six months or longer.
In November, Lyell acquired the rights to another CAR-T treatment, LYL273, for metastatic colorectal cancer, from Innovative Cellular Therapeutics.
ResearchAndMarkets.com also recently projected the market for CAR-T therapies will grow to $13.25B by 2030 from $3.87B. in 2024.

More on Lyell Immunopharma